This work is dedicated to my husband, Andrew Wilson, whose encouragement of me to enroll in the MSCI program, and unflagging optimism and support, made the completion of this work possible. Results: Of the 9,748 patients hospitalized with ADHF during the years under study, 35.9% had a history of COPD. The average age of this population was 76.1 years, 43.9% were men, and 93.3% were white. At the time of hospital discharge, patients with COPD were less likely to have received evidence-based heart failure medications, including beta-blockers and ACE inhibitors/angiotensin receptor blockers, than patients without COPD. Multivariable adjusted in-hospital death rates were similar for patients with and without COPD. However, among patients who survived to hospital discharge, patients with COPD had a significantly higher risk of dying at 1 (adjusted RR 1.10; 95% CI 1.06, 1.14) and 5-years (adjusted RR 1.40; 95% CI 1.28, 1.42) after hospital discharge than patients who were not previously diagnosed with COPD.
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CHAPTER I Introduction
Heart failure and chronic obstructive lung disease are leading causes of morbidity and mortality worldwide. [1] [2] [3] The two diseases often coexist, 4, 5 owing to shared key predisposing factors, including the smoking of tobacco and advanced age. Chronic obstructive pulmonary disease (COPD) is one of the most common co-morbidities in patients with heart failure (HF) with a prevalence of 20-30%. [6] [7] [8] [9] [10] There is increasing recognition of the prognostic and therapeutic importance of the co-morbid conditions associated with HF. 10 The presence of COPD in patients with HF has been associated with poor clinical outcomes 7, 11 and the management of HF is complicated by the presence of COPD. The cornerstones of therapy for HF and COPD, beta-blockers and beta-agonists, have opposing pharmacologic actions, raising concerns that the treatment of one condition may worsen the other. Despite a growing evidence base demonstrating the safety of cardioselective beta-blockade in patients with COPD, 12, 13 patients with COPD and HF are less likely to receive several guideline recommended therapies for HF. 7, 8, 11, 14 For these and other reasons, COPD is expected to be an important co-morbidity in patients with HF, with the potential to negatively influence the treatment and mortality of patients hospitalized with acute decompensated heart failure (ADHF).
Despite the importance of co-morbid COPD on treatment and mortality of HF, data describing the clinical epidemiology of patients with HF and coexistent COPD from the more generalizable perspective of a population-based investigation are extremely limited. 8, 11 Most prior studies examining the association between COPD and HF have utilized a registry-based design, or have been carried out as secondary analyses of data from randomized controlled trials, with more select patient populations. 7, 11, 15 The only community-based study examining the impact of COPD on mortality in patients with ADHF, conducted in the Somme region of France in 2000, studied a relatively small patient population (n = 799). 8 The primary objective of this study was to describe the impact of COPD on the in-hospital and long-term mortality and treatment of patients hospitalized with acute decompensated heart failure (ADHF) from a community-wide perspective, utilizing a large observational dataset. A secondary aim was to examine decade long trends (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) in the survival and treatment patterns of patients with ADHF according to COPD status. Data from the population-based Worcester Heart Failure Study were utilized for purposes of this study. 16, 17 CHAPTER II
Study methods
Study population
The Worcester Heart Failure study is a population-based investigation that [14] [15] [16] [17] [18] [19] These years were selected due to the availability of grant funding and for purposes of describing decade long trends in the descriptive epidemiology of ADHF. Details of this study have been previously provided. [15] [16] [17] [18] [19] [20] This study was approved by the Institutional Review Board at the University of Massachusetts Medical School (IRB approval #10398 1).
In order to identify cases of possible ADHF, the medical records of patients discharged with a primary or secondary International Classification of Disease (ICD)-9 code consistent with HF were reviewed by trained study physicians and nurses. The presence of HF as the primary cause of hospitalization was confirmed using pre-established Framingham criteria 18, 19 and determination was made whether the index hospitalization during the years under study was the first (incident) episode of HF or otherwise. Medical records of patients with discharge diagnoses of hypertensive heart and renal disease, acute cor pulmonale, cardiomyopathy, pulmonary congestion, acute lung edema, and respiratory abnormalities were also reviewed to identify patients who may also have had new onset ADHF. 16 Patients who developed HF during hospitalization for another acute illness (e.g., acute myocardial infarction) or after an interventional procedure (e.g., coronary artery bypass surgery) were not included in this study. COPD was considered to be present if a patient was described in his/her medical record as having clinical or radiographic evidence of COPD.
Pulmonary function testing results were not available to confirm the diagnosis or to assess the severity of COPD. were not included in our regression models. All analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, North Carolina).
CHAPTER III
Study findings
Study Population Characteristics A total of 9,748 patients were hospitalized with ADHF at all metropolitan Worcester medical centers during the years under study of whom 3,500 (35.9%) had a history of COPD. Overall, the mean age of the study population was 76. 
Hospital Discharge Treatment Practices
Patients with COPD were less likely to have been treated with most classes of HF specific medications at the time of hospital discharge than patients without COPD. These included ACE inhibitors/angiotensin receptor blockers (ACE-I/ARBs) and beta-blockers. Patients with COPD were slightly more likely to have been treated with diuretics on discharge than patients without COPD.
There were no significant differences in the use of nitrates and hydralazine between patients with and without COPD; however, very few patients (< 1%) in either group were treated with this combination of medications ( Table 3 .
2).
After restricting our sample to the subset of patients with ADHF and a 
In-Hospital Death Rates
Patients with previously diagnosed COPD had higher in-hospital death rates compared to patients without COPD (7.9% vs. 6.8%, p = 0.05). After adjusting for differences in several baseline demographic and clinical characteristics, differences in hospital death rates were no longer statistically significant (RR 0.99, 95% C.I. 0.98, 1.00) ( (Figure 3. 2), in in-hospital survival.
Post Discharge Death Rates
Among patients who survived to hospital discharge, patients with COPD were more likely to have died over the course of our extended follow-up (Figure
3.3).
While there were no differences in our multivariable adjusted death rates at 30 days after hospital discharge (RR 1.01, 95% C.I. * Adjusted for age, sex, white race, incident vs. previously diagnosed HF, length of hospital stay, prior vascular disease (history of stroke, peripheral vascular disease, angina, or coronary artery bypass surgery), prior other co-morbidities (diabetes, hypertension, renal disease, anemia, and atrial fibrillation), smoking status, and physiologic variables on presentation (blood pressure, sodium, creatinine).
•Relative risk (RR) of selected endpoints in patients with, as compared to those without, COPD. Patients without COPD comprised the referent group A.
B.
C.
Figure 3.1 Legend.
A, Beta-blockers. B, ACE-inhibitor or angiotensin receptor blocker. C, Diuretic therapy * Adjusted for age, sex, white race, incident HF, length of hospital stay, prior vascular disease (history of stroke, peripheral vascular disease, angina, or coronary artery bypass surgery), prior other co-morbidities (diabetes, hypertension, renal disease, anemia, and atrial fibrillation), smoking status, and laboratory and physiologic variables on presentation (blood pressure, sodium, creatinine). Study year 1995 comprised the referent group. 
CHAPTER IV Discussion
In this large, community-based, study of residents of central
Massachusetts hospitalized with ADHF, we found COPD to be a common comorbidity, affecting approximately one in every three patients with ADHF. We observed significant differences between patients with and without COPD with regards to co-morbidity burden, presenting clinical characteristics, medications prescribed at hospital discharge, and all-cause mortality. COPD was associated with an increased risk of dying over the long-term in the setting of ADHF. While long-term survival following hospital discharge improved in patients with and without a history of COPD during the decade long period under study (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) , patients with ADHF and co-existent COPD continued to fare worse than those without COPD. We found a marked increase in the use of beta-blockers at the time of discharge in all patients during the years under study; however, a gap in the use of these medications persisted between patients with and without prior COPD, independent of HF classification based on echocardiographic findings.
Prevalence of COPD in ADHF and Clinical Characteristics
Approximately one-third of patients hospitalized for ADHF in our study had a prior history of COPD. This proportion is slightly higher than the findings from other observational studies which found prevalence estimates to have ranged from 10% to upwards of 25%. [6] [7] [8] 10, 11, 20, 21 In one of the only other communitybased studies of COPD in patients with HF, 20% of 799 patients hospitalized with HF at any of the 11 healthcare establishments responsible for managing patients with HF in the Somme region of France during 2000 had co-existing COPD. This study was, however, limited to patients with a first episode of HF which likely accounted for the lower observed prevalence of COPD than was observed in our study. 8 Although the prevalence of COPD in patients with HF has been noted to be higher in more recent studies, 20 we were encouraged that the prevalence of
COPD in residents of central Massachusetts hospitalized at all metropolitan
Worcester medical centers remained stable during the decade long period under study.
Patients with COPD had a higher burden of vascular co-morbidities, likely related to increased rates of smoking which is a common risk factor for these conditions; COPD itself may also be an independent risk factor for cardiovascular morbidity, although our study was not designed to address this. 22 In contrast to prior studies, 7, 8 patients with COPD in the present investigation were slightly more likely to have a preserved ejection fraction (HFpEF). Interpretation of this finding is limited, however, by the substantial rate of missing echocardiographic data in our study population, rates of which differed according to COPD status.
However, emphysema and airflow obstruction have been shown to impair left ventricular filling without association with EF, suggesting a potential mechanism by which COPD may predispose patients to HFpEF. It is possible that the observed differences in beta-blocker use at the time of hospital discharge were related to patients with COPD being less likely to have heart failure with reduced EF (HFrEF) (EF < 40%) and, therefore, not having a definite indication for treatment with beta-blockers. However, the observed differences in beta-blocker use persisted even after restricting our analysis to patients with documented HFrEF, suggesting that even among the subset of patients proven to benefit from beta-blocker treatment, patients with COPD were less likely to have received this evidence based therapy. Because echocardiographic data were only available on a subset of patients, and the use of echocardiography differed according to COPD status, this subgroup analysis should be interpreted with appropriate caution, however. Nonetheless, in light of data demonstrating the safety of cardioselective beta-blockers in patients with COPD, 12,13 sustained educational efforts of health care professionals are needed to ensure that potential gaps in treatment are eliminated.
We also observed a significant difference in hospital prescribing practices in the use of ACE-I/ARB medications between patients with and without COPD.
This finding may be accounted for by the increased prevalence of renal disease among patients with COPD, lower presenting blood pressure, or more frequently preserved ejection fraction. Our finding that ACE-I/ARB treatment did not differ between patients with and without COPD when restricted to those with HFrEF supports the notion that differences in heart failure classification (HFpEF vs.
HFrEF), and, therefore, indications for ACE-I/ARB use, account at least in part for the observed differences in use of this class of medications between patients with and without COPD.
Consistent with the findings from several other studies, we found a slightly higher rate of use of diuretics in patients with ADHF and concomitant COPD. [6] [7] [8] 11, 23 This may reflect increased volume overload in these patients related to concomitant steroid use, or the presence of pulmonary hypertension and right heart failure. The present results suggest that the use of several classes of HF specific medications differs between patients with and without COPD. These differences may reflect the complex physiologic interactions between COPD and ADHF, 24 resulting in differing requirements for, and responses to, HF specific medications.
In-Hospital and Post Discharge Death Rates
We found that patients with a history of COPD had similar short-term (inhospital and 30-days post-discharge) mortality as patients without COPD.
However, COPD was associated with a substantially worse long-term prognosis.
This is in keeping with the results from other observational studies which have found increased long-term death rates in patients hospitalized with HF and concomitant COPD. 7, 8, 10, 21 Because we did not have spirometric data available to confirm the diagnosis of COPD, our findings are subject to potential misclassification bias; however, this is expected to reduce the magnitude of the association between COPD and the observed increased risk of dying over the long-term period of follow-up. Thus, it is possible that COPD confers an even greater risk of dying following hospitalization for ADHF than we have observed.
In addition, measures of the severity of COPD (FEV1 and GOLD stage) have been shown to be independent predictors of mortality and event-free survival, respectively, in patients with COPD and concomitant HF. 9, 25 Therefore, the degree of increased mortality associated with COPD in ADHF is dependent on the severity of COPD. Our study is limited in not being able to quantify the severity of COPD; however, the community-based nature of this investigation is expected to have included individuals with varying degrees of COPD severity and, therefore, may provide a more reliable estimate of the short and long-term impact of COPD on prognosis in patients with HF than studies with more highly selected patient populations.
The impact of COPD on mortality in patients with ADHF appears to have been more pronounced over the long term. For example, while there were no differences in short-term death rates during the first 30-days after hospital discharge, there was a 10% increased risk of dying at 1 year, and 40% at 5 years post-discharge, in patients with, as compared to those without, COPD. between patients with and without COPD. 6 Similarly, in a community-wide study of patients hospitalized with newly diagnosed HF in the Somme region of France in 2000, there was no significant impact of COPD on short-term survival.
Consistent with our findings, this study demonstrated a significant association between COPD and long-term mortality with an approximately 50% lower 5-year survival rate observed among patients with, as compared to those without, previously diagnosed COPD. 8 Prior studies have suggested that the severity of ADHF at the time of hospital presentation is strongly associated with early mortality. 16 Thus, one possible explanation for these findings is that short-term mortality is predominantly influenced by ADHF presenting characteristics, whereas comorbidities such as COPD may be stronger determinants of long-term outcomes.
Although our study did not assess the cause of death, this supposition is supported by the findings from other studies in which the excess mortality associated with COPD in patients with ADHF was mainly non-cardiac in etiology. 15 Further studies are needed to determine and address the factors leading to increased long-term mortality in patients with COPD and ADHF.
The present study is unique in examining changing trends in a variety of descriptive patient characteristics, treatment practices, and outcomes over a decade long period (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) . We observed improvements in survival over time in all patients with ADHF, but there was a larger improvement in survival among patients without, as compared to those with, COPD. Although our study was not designed to explain which factors influenced the observed decreases in mortality, these results suggest that the overall quality of care of patients with ADHF may be either more consistently applied to, or more effective in, patients without COPD. For example, patients with COPD were less likely to have received evidence-based HF medications on discharge. In addition, these patients were more likely to have a preserved ejection fraction, and there have been fewer advances in the treatment of patients with preserved ejection fraction during this time period than for those with reduced ejection fraction findings. 26, 27 Study strengths and limitations
The primary strength of this study was the large sample of patients with independently validated hospitalizations for ADHF from the perspective of a large community-based investigation, with collection of detailed clinical characteristics and excellent rates of long-term follow up. Limitations include the lack of spirometric data to confirm the diagnosis of COPD. However, numerous prior studies of COPD and HF have defined COPD in a similar manner. 6-8, 11 We did not collect data on the specific causes of mortality and were, therefore, unable to determine if the increased mortality observed in patients with COPD was cardiac or non-cardiac in etiology. We did not include patients who developed HF during hospitalization for another illness and are, therefore, unable to comment on how COPD status might differentially impact patients who develop HF in this context. 2004; however, these improvements were greater for patients without COPD than for those with co-existent COPD. Further studies are needed to better understand how to optimize the long-term outpatient treatment for patients with COPD and ADHF and address the causes of increased mortality in these patients.
